ReviewFrontiers in ophthalmology2026
Posterior segment imaging clues to systemic malignancy: a phenotype-to-confirmation narrative review.
Review in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic malignancies may affect the posterior segment through metastatic, paraneoplastic, hematologic or lymphomatous, and treatment-related mechanisms. Because routine ophthalmic imaging rarely establishes the underlying etiology, its principal clinical value is to identify suspicious patterns, prioritize competing diagnoses, and guide further investigation. This narrative review synthesizes malignancy-related posterior segment findings and proposes a clinically oriented phenotype-to-confirmation framework for multimodal interpretation. A literature search was conducted in PubMed, Scopus, and Web of Science for publications from January 2000 to May 18, 2026. The review included choroidal metastasis, paraneoplastic retinopathies and choroidopathies, vitreoretinal lymphoma, hematologic infiltration, leukemic retinopathy, and anticancer therapy-related toxicity. Owing to heterogeneity in disease entities, imaging protocols, diagnostic confirmation, and study designs, the evidence was synthesized qualitatively. Findings were organized into five suspicion-triggering phenotypes: exudative choroidal mass, RPE-choroidal remodeling, vitreoretinal infiltrative, diffuse neuroretinal dysfunction, and treatment-imprint phenotypes. Each phenotype was linked to its principal mimickers and to appropriate additional investigations, including targeted multimodal imaging, electrophysiology, ocular-fluid analysis, molecular testing, or systemic oncologic reassessment. These phenotypes should not be regarded as validated diagnostic categories, but as clinical entry points for differential exclusion and diagnostic escalation. Artificial intelligence may eventually support image registration, lesion tracking, and longitudinal comparison; however, its role in these rare and heterogeneous disorders remains investigational.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.